Yingqiang Zhang

6PUBLICATIONS
0CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 08, 2024
A real-world study of tyrosine kinase inhibitors plus anti-PD-1 immunotherapy with or without chemoembolization for hepatocellular carcinoma patients with main portal vein invasion.

Ze Song, De-Di Wu, Wen-Zhe Fan

|May 05, 2021
Radiologic Response Combined with Dermatologic Toxicities is the Most Robust Predictor of Survival Benefits in Patients with Inoperable Hepatocellular Carcinoma After Transarterial Chemoembolization Plus Sorafenib Therapy.

Zhiqiu Ye, Zhizhen Deng, Suxiang Jiang

|Jan 02, 2021
A prognostic score model for predicting the survival benefits of patients undergoing sorafenib plus transarterial chemoembolization for hepatocellular carcinoma with portal vein invasion.

Ji-Rong Li, Min-Jiang Wu, Tan Wang

|Aug 06, 2020
Apatinib treatment may improve survival outcomes of patients with hepatitis B virus-related sorafenib-resistant hepatocellular carcinoma.

Yingqiang Zhang, Guihua Huang, Hongfei Miao

|Aug 31, 2019
Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study.

Yingqiang Zhang, Wenzhe Fan, Yu Wang

|Jun 29, 2019
Alpha-fetoprotein assessment for hepatocellular carcinoma after transarterial chemoembolization.

Min Tian, Xiaoying Zhang, Guihua Huang

Pageof 1

Frequent Collaborators